CN107773564A - A kind of pharmaceutical composition of antipyretic-antalgic - Google Patents
A kind of pharmaceutical composition of antipyretic-antalgic Download PDFInfo
- Publication number
- CN107773564A CN107773564A CN201610728543.4A CN201610728543A CN107773564A CN 107773564 A CN107773564 A CN 107773564A CN 201610728543 A CN201610728543 A CN 201610728543A CN 107773564 A CN107773564 A CN 107773564A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- antipyretic
- antalgic
- aminopyrine
- phenacetin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition of antipyretic-antalgic, it is characterised in that the pharmaceutical composition is made up of aminopyrine, phenacetin, caffeine, phenobarbital and pharmaceutic adjuvant.Wherein aminopyrine and phenacetin can suppress the synthesis and release of hypothalamus prostaglandin, recover the orthocrasia of heat-regulating centers receptive neuron and play antipyretic effect；Also play analgesic activity by suppressing the synthesis of prostaglandin etc. simultaneously.Aminopyrine and the synthesis and release that can suppress prostaglandin in inflammation local organization, stable lysosomal enzyme, influence the phagocytosis of phagocyte and play antiinflammatory action.Coffee the excited cerebral cortex of energy, improves the irritability to the external world because nervous stimulants, and has the contraction cerebrovascular, and two medicines alleviate the effect of headache before reinforcement.Phenobarbital has calmness, hypnosis, anticonvulsant action, can strengthen the analgesic activity of aminopyrine and phenacetin, and prevents the convulsions caused by heating.
Description
Technical field
The invention belongs to field of medicine preparations, and in particular to a kind of pharmaceutical composition of antipyretic-antalgic.
Background technology
Somedon also known as analgesia piece or somidon, are a kind of compound preparations, main component has phenacetin, caffeine, benzene
Barbital etc..Phenobarbital in somedon has sedative-hypnotic effect, can improve pain stimulation effect, but long-term use is very
Easy habituation.In addition, the phenacetin, aminopyrine in somedon have obvious adverse reaction.Long-term use can cause liver kidney
Function damage.How reasonably combined prescription, the drug side-effect for reducing somedon is the problem to be solved in the present invention.
The content of the invention
A kind of the present invention is intended to provide pharmaceutical composition of antipyretic-antalgic.
For achieving the above object, a kind of pharmaceutical composition of antipyretic-antalgic of the present invention, its specific embodiment are：
A kind of pharmaceutical composition of antipyretic-antalgic of the present invention, it is characterised in that the pharmaceutical composition by aminopyrine, it is non-that
Western fourth, caffeine, phenobarbital and pharmaceutic adjuvant composition.
A kind of pharmaceutical composition of antipyretic-antalgic of the present invention, the pharmaceutical composition prescription percentage by weight are calculated as：Ammonia
Ji Bilin 10-50%, phenacetin 10-50%, caffeine 5-15%, phenobarbital 1-10%, pharmaceutic adjuvant 1-15%.
A kind of pharmaceutical composition of antipyretic-antalgic of the present invention, the pharmaceutical composition prescription percentage by weight are calculated as：Ammonia
Ji Bilin 15-35%, phenacetin 15-35%, caffeine 8-11%, phenobarbital 1-5%, pharmaceutic adjuvant 5-15%.
A kind of pharmaceutical composition of antipyretic-antalgic of the present invention, the pharmaceutical composition prescription percentage by weight are calculated as：Ammonia
Ji Bilin 35%, phenacetin 35%, caffeine 11%, phenobarbital 4%, pharmaceutic adjuvant 15%.
A kind of pharmaceutical composition of antipyretic-antalgic of the present invention, the pharmaceutical composition are granule, capsule, tablet.
A kind of pharmaceutical composition of antipyretic-antalgic of the present invention, the preparation method of the medicinal composition tablets are：
1）Take phenacetin, caffeine to mix 80 mesh sieves that were milled by recipe quantity, separately take phenobarbital, starch to be mixed by recipe quantity
Be milled 100 mesh sieves, and two kinds of compounds mix barrelling in proportion again, standby（For PC grain compounds）；
2）Aminopyrine is taken to be milled 100 mesh sieves, it is standby by recipe quantity to mix barrelling with starch（For A grain compounds）；
3）Above-mentioned PC compounds, A compounds degree of granulation respectively, dry；
4）Bis- kinds of dry granulars of A, PC are mixed in proportion and add magnesium stearate mixing, with 14 mesh nylon mesh whole grains, mixes, uses 11.5mm
Hypotenuse plane punch die tabletting.
A kind of pharmaceutical composition of antipyretic-antalgic of the present invention, the preparation method step 3 of the medicinal composition tablets）
For：Take compound put it is dry in mixer stir 10-15 minutes, add 15% starch slurry stir 15-20 minutes, softwood is made, with 14
Mesh nylon mesh is pelletized, in 70-80 DEG C of temperature aeration-dryings.
A kind of pharmaceutical composition of antipyretic-antalgic of the present invention, the preparation method step 3 of the medicinal composition tablets）
For：Dry granular water content control is below 2.0%.
The pharmaceutical composition of the invention is made up of aminopyrine, phenacetin, caffeine, phenobarbital and pharmaceutic adjuvant.
Wherein aminopyrine and phenacetin can suppress the synthesis and release of hypothalamus prostaglandin, recover heat-regulating centers impression god
Antipyretic effect is played through first orthocrasia；Also play analgesic activity by suppressing the synthesis of prostaglandin etc. simultaneously.Amino
Than woods and the synthesis and release of prostaglandin in inflammation local organization can be suppressed, stable lysosomal enzyme, influence gulping down for phagocyte
Bite and act on and play antiinflammatory action.Coffee the excited cerebral cortex of energy, improves the sensing to the external world because nervous stimulants
Property, and having the contraction cerebrovascular, two medicines alleviate the effect of headache before reinforcement.Phenobarbital has calmness, hypnosis, anticonvulsant action,
The analgesic activity of aminopyrine and phenacetin can be strengthened, and prevent the convulsions caused by heating.
The present invention effectively reduces side effects of pharmaceutical drugs by reasonably combined prescription and dosage.
Embodiment
Example below is only of the invention to further illustrate, scope that the invention is not limited in any way.
Embodiment 1
Prescription（It is made 1000）：
Main ingredient：Aminopyrine 140g phenacetins 140g
Caffeine 44g phenobarbitals 15g
Auxiliary material：Starch 30.5g magnesium stearates 0.875g
Starch slurry (10%) 13-15g
Embodiment 2
Prescription（It is made 1000）：
Main ingredient：Aminopyrine 120g phenacetins 120g
Caffeine 35g phenobarbitals 12g
Auxiliary material：Starch 40.5g magnesium stearates 0.675g
Starch slurry (10%) 23-25g
Embodiment 3
Prescription（It is made 1000）：
Main ingredient：Aminopyrine 135g phenacetins 135g
Caffeine 40g phenobarbitals 12g
Auxiliary material：Starch 40.5g magnesium stearates 0.675g
Starch slurry (10%) 23-25g
Embodiment 1-3 preparation methods：
1st, phenacetin, caffeine is taken to mix 80 mesh sieves that were milled by recipe quantity.Separately phenobarbital, starch is taken to be mixed by recipe quantity
Be milled 100 mesh sieves.Right latter two compound mixes barrelling in proportion again, standby（For PC grain compounds）.
2nd, aminopyrine is taken to be milled 100 mesh sieves, it is standby by recipe quantity to mix barrelling with starch（For A grain compounds）.
3rd, above-mentioned PC compounds, A compounds degree of granulation respectively, dry.Method is as follows：Take compound put it is dry in mixer stir 10-
15 minutes, add 15% starch slurry and stir 15-20 minutes, softwood is made, pelletized with 14 mesh nylon mesh, led in 70-80 DEG C of temperature
Air-dry dry.Dry granular water content control is below 2.0%.
4th, bis- kinds of dry granulars of A, PC are mixed in proportion and adds magnesium stearate mixing, with 14 mesh nylon mesh whole grains, mixed.Calculate
Piece weight.Sample censorship.
4th, with 11.5mm hypotenuse plane punch die tablettings.
5th, pack.
Experimental example：Stability experiment
1. accelerated test data（Embodiment 1）：
2. accelerated test data（Embodiment 2）
3. accelerated test data（Embodiment 3）
Result above shows that under these conditions, sample property and content illustrate that the prescription and technique can be very without significant change
The stability of medicine is improved well.
Claims (8)
1. a kind of pharmaceutical composition of antipyretic-antalgic, it is characterised in that the pharmaceutical composition is by aminopyrine, phenacetin, coffee
Cause, phenobarbital and pharmaceutic adjuvant composition.
A kind of 2. pharmaceutical composition of antipyretic-antalgic according to claim 1, it is characterised in that the pharmaceutical composition prescription weight
Measuring percentages is：Aminopyrine 10-50%, phenacetin 10-50%, caffeine 5-15%, phenobarbital 1-10%, pharmaceutic adjuvant
1-15%。
A kind of 3. pharmaceutical composition of antipyretic-antalgic according to claim 1, it is characterised in that the pharmaceutical composition prescription weight
Measuring percentages is：Aminopyrine 15-35%, phenacetin 15-35%, caffeine 8-11%, phenobarbital 1-5%, pharmaceutic adjuvant
5-15%。
A kind of 4. pharmaceutical composition of antipyretic-antalgic according to claim 1, it is characterised in that the pharmaceutical composition prescription weight
Measuring percentages is：Aminopyrine 35%, phenacetin 35%, caffeine 11%, phenobarbital 4%, pharmaceutic adjuvant 15%.
5. according to a kind of any one of claim 1-4 pharmaceutical compositions of antipyretic-antalgic, it is characterised in that the drug regimen
Thing is granule, capsule, tablet.
6. a kind of pharmaceutical composition of antipyretic-antalgic according to claim 5, it is characterised in that the medicinal composition tablets
Preparation method is：
Take phenacetin, caffeine to mix 80 mesh sieves that were milled by recipe quantity, separately take phenobarbital, starch to mix and grind by recipe quantity
Powder crosses 100 mesh sieves, and two kinds of compounds mix barrelling in proportion again, standby（For PC grain compounds）；
Aminopyrine is taken to be milled 100 mesh sieves, it is standby by recipe quantity to mix barrelling with starch（For A grain compounds）；
Above-mentioned PC compounds, A compounds degree of granulation respectively, dry；
Bis- kinds of dry granulars of A, PC are mixed in proportion and add magnesium stearate mixing, with 14 mesh nylon mesh whole grains, are mixed, it is oblique with 11.5mm
Side plane punch die tabletting.
7. a kind of pharmaceutical composition of antipyretic-antalgic according to claim 6, it is characterised in that the medicinal composition tablets
Preparation method step 3）For：Take compound put it is dry in mixer stir 10-15 minutes, add 15% starch slurry stir 15-20 points
Clock, softwood is made, is pelletized with 14 mesh nylon mesh, in 70-80 DEG C of temperature aeration-dryings.
8. a kind of pharmaceutical composition of antipyretic-antalgic according to claim 7, it is characterised in that the medicinal composition tablets
Preparation method step 3）For：Dry granular water content control is below 2.0%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610728543.4A CN107773564A (en) | 2016-08-26 | 2016-08-26 | A kind of pharmaceutical composition of antipyretic-antalgic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610728543.4A CN107773564A (en) | 2016-08-26 | 2016-08-26 | A kind of pharmaceutical composition of antipyretic-antalgic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107773564A true CN107773564A (en) | 2018-03-09 |
Family
ID=61439748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610728543.4A Pending CN107773564A (en) | 2016-08-26 | 2016-08-26 | A kind of pharmaceutical composition of antipyretic-antalgic |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107773564A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106478445A (en) * | 2016-11-07 | 2017-03-08 | 华中药业股份有限公司 | A kind of preparation method of phenacetin micropowder |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1243723A (en) * | 1998-08-04 | 2000-02-09 | 卢子钧 | Quickly-acting antalgic ointment |
| CN1954833A (en) * | 2005-10-24 | 2007-05-02 | 王明贤 | Medicine for treating toothache |
| CN104606204A (en) * | 2015-02-11 | 2015-05-13 | 湖南中医药大学 | Febrifuge for children |
| CN104857001A (en) * | 2015-04-30 | 2015-08-26 | 重庆市中药研究院 | External preparation for curing dermatophytosis and preparation method thereof |
| CN104857000A (en) * | 2015-04-30 | 2015-08-26 | 重庆市中药研究院 | Drug for curing dermatophytosis and preparation method thereof |
-
2016
- 2016-08-26 CN CN201610728543.4A patent/CN107773564A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1243723A (en) * | 1998-08-04 | 2000-02-09 | 卢子钧 | Quickly-acting antalgic ointment |
| CN1954833A (en) * | 2005-10-24 | 2007-05-02 | 王明贤 | Medicine for treating toothache |
| CN100484535C (en) * | 2005-10-24 | 2009-05-06 | 王明贤 | Medicine for treating toothache |
| CN104606204A (en) * | 2015-02-11 | 2015-05-13 | 湖南中医药大学 | Febrifuge for children |
| CN104857001A (en) * | 2015-04-30 | 2015-08-26 | 重庆市中药研究院 | External preparation for curing dermatophytosis and preparation method thereof |
| CN104857000A (en) * | 2015-04-30 | 2015-08-26 | 重庆市中药研究院 | Drug for curing dermatophytosis and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 孟胜男主编: "《药剂学》", 30 September 2011 * |
| 山西同达药业有限公司: ""去痛片"", 《国家药品监督管理局官网》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106478445A (en) * | 2016-11-07 | 2017-03-08 | 华中药业股份有限公司 | A kind of preparation method of phenacetin micropowder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101360493A (en) | Levetiracetam formulations and methods for their manufacture | |
| CN1736471A (en) | Ginger preparation and preparation process thereof | |
| CN107773564A (en) | A kind of pharmaceutical composition of antipyretic-antalgic | |
| CN102793685A (en) | Oral capsule containing pregabalin and preparation method thereof | |
| CN101744852A (en) | Preparation method of acanthopanax effervescent tablet and products thereof | |
| CN105125621A (en) | Oral composition with immunity enhancement function | |
| CN104543662B (en) | A kind of production method of hypoglycemic coprinus comatus polyoses grain | |
| CN114288259B (en) | Quick-release preparation of vitamin B2 and preparation method thereof | |
| CN106214643A (en) | Compound recipe sodium citrate dissipates and preparation method thereof | |
| CN108014085A (en) | A kind of preparation method and applications of sabril solid composite | |
| CN104814957A (en) | Lesinurad-containing compound composition and preparation method thereof | |
| CN115475227A (en) | Pharmaceutical composition and dosage form for treating gout | |
| CN106176655A (en) | A kind of penicillin V potassium and preparation technology thereof | |
| CN109875979A (en) | A kind of metho kahuangmin sustained release pellet and preparation method thereof | |
| CN103948606B (en) | Akafen powder and preparation method thereof | |
| CN111374953A (en) | Paracetamol tablet and preparation process thereof | |
| KR100735904B1 (en) | Tablet composition containing extract of natural herbal plants and its manufacturing process | |
| CN100586432C (en) | Yiganling dispersion tablet for treating liver disease and its preparation method | |
| CN101861973A (en) | Method for uniformly dispersing and effectively dissolving low-dose and indissoluble active ingredients in preparation out | |
| CN104474169B (en) | A kind of Ge Shan blood-fat-lowering granule and preparation method thereof | |
| JPS6185331A (en) | Production of excipient for direct tableting | |
| CN109692163A (en) | A kind of preparation method of gan fu le oral preparation | |
| CN100512815C (en) | Matrine enteric coatel tablet and its preparation method | |
| CN105534980A (en) | Pharmaceutical composition of repaglinide and metformin hydrochloride and preparation technology of pharmaceutical composition | |
| CN104622929A (en) | Composition containing ginseng and lucid ganoderma and preparation method of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180309 |